Correlation Between GlaxoSmithKline PLC and Us Strategic

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both GlaxoSmithKline PLC and Us Strategic at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining GlaxoSmithKline PLC and Us Strategic into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between GlaxoSmithKline PLC ADR and Us Strategic Equity, you can compare the effects of market volatilities on GlaxoSmithKline PLC and Us Strategic and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in GlaxoSmithKline PLC with a short position of Us Strategic. Check out your portfolio center. Please also check ongoing floating volatility patterns of GlaxoSmithKline PLC and Us Strategic.

Diversification Opportunities for GlaxoSmithKline PLC and Us Strategic

-0.89
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between GlaxoSmithKline and RUSTX is -0.89. Overlapping area represents the amount of risk that can be diversified away by holding GlaxoSmithKline PLC ADR and Us Strategic Equity in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Us Strategic Equity and GlaxoSmithKline PLC is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on GlaxoSmithKline PLC ADR are associated (or correlated) with Us Strategic. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Us Strategic Equity has no effect on the direction of GlaxoSmithKline PLC i.e., GlaxoSmithKline PLC and Us Strategic go up and down completely randomly.

Pair Corralation between GlaxoSmithKline PLC and Us Strategic

Considering the 90-day investment horizon GlaxoSmithKline PLC ADR is expected to under-perform the Us Strategic. In addition to that, GlaxoSmithKline PLC is 1.54 times more volatile than Us Strategic Equity. It trades about -0.33 of its total potential returns per unit of risk. Us Strategic Equity is currently generating about 0.18 per unit of volatility. If you would invest  1,810  in Us Strategic Equity on August 27, 2024 and sell it today you would earn a total of  62.00  from holding Us Strategic Equity or generate 3.43% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

GlaxoSmithKline PLC ADR  vs.  Us Strategic Equity

 Performance 
       Timeline  
GlaxoSmithKline PLC ADR 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days GlaxoSmithKline PLC ADR has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in December 2024. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.
Us Strategic Equity 

Risk-Adjusted Performance

11 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Us Strategic Equity are ranked lower than 11 (%) of all funds and portfolios of funds over the last 90 days. In spite of fairly weak basic indicators, Us Strategic may actually be approaching a critical reversion point that can send shares even higher in December 2024.

GlaxoSmithKline PLC and Us Strategic Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with GlaxoSmithKline PLC and Us Strategic

The main advantage of trading using opposite GlaxoSmithKline PLC and Us Strategic positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if GlaxoSmithKline PLC position performs unexpectedly, Us Strategic can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Us Strategic will offset losses from the drop in Us Strategic's long position.
The idea behind GlaxoSmithKline PLC ADR and Us Strategic Equity pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Other Complementary Tools

Stocks Directory
Find actively traded stocks across global markets
Transaction History
View history of all your transactions and understand their impact on performance
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Commodity Directory
Find actively traded commodities issued by global exchanges
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance